Board of Directors

Yuling Luo is the chief executive officer and chair of Alamar Biosciences. Prior to co-founding Alamar, Yuling co-founded Advanced Cell Diagnostics (ACD) where he served as president and chief executive officer until its acquisition by Bio-Techne. At ACD, he invented RNAscope, a breakthrough molecular detection technology that has pioneered spatial biology and become the gold standard in RNA tissue imaging. Prior to ACD, Yuling co-founded Panomics, a life science company that was acquired by Affymetrix, where he served in various roles including Chief Scientific Officer. He co-founded and served as board chair Avida Biomed (acquired by Agilent) and co-founded and serves as board chair for Attovia Therapeutics. Yuling is a venture partner of Illumina Ventures, has published numerous research papers in top peer-reviewed journals and his inventions are the subject of over 30 issued patents. He received a B.S. in Chemistry from the University of Science & Technology of China and earned a Ph.D. in Biochemistry from Case Western Reserve University.

Rebecca Chambers has served as a member of our board of directors since January 2026. She is currently executive vice president and chief financial officer of Veracyte. Prior to Veracyte, she served as chief financial officer of Outset Medical and held a series of senior finance roles at Illumina, including vice president of financial planning and analysis and vice president of investor relations and treasury. Earlier in her career, she held finance and investor relations roles at Myriad Genetics and Life Technologies. She previously served on the board of Inari Medical until its acquisition by Stryker. Rebecca holds a B.S. in Biology from John Carroll University and an M.B.A. from the S.C. Johnson Graduate School of Management at Cornell University.

Steve Chen is a co-founder and the chief operating officer of Alamar. Prior to Alamar, he was co-founder of Advanced Cell Diagnostics (ACD) where he served as chief operating officer until its acquisition by Bio-Techne. Earlier in his career, Steve co-founded Panomics where he also served as chief technology officer. Before joining industry, he was an assistant professor at University of Maryland, College Park where he conducted research in the field of optical sensors and instrumentation. His research and development work has resulted in several dozen peer-reviewed journal publications and more than 20 issued patents. Steve holds a B.S. in Precision Instrumentation Engineering from the University of Science and Technology of China and a Ph.D. in Electronic Engineering from University of London.

Nicholas Naclerio has served as a member of our board of directors since May 2020. Dr. Naclerio is the Founding Partner of Illumina Ventures, a position he has held since April 2016. Dr. Naclerio currently serves on 151 the boards of directors of a number of privately held companies. Earlier in his career, Dr. Naclerio served as Senior Vice President, Corporate & Venture Development of Illumina, Inc., a genomics company, from July 2010 to April 2015. Dr. Naclerio also co-founded Quanterix Corporation, a diagnostics company, and served as the Chairman of the Board and Chief Executive Officer from 2007 to 2010. Dr. Naclerio received his B.S. in Electrical Engineering/Computer Science from Duke University and a Ph.D. in Electrical Engineering from the University of Maryland College Park. Dr. Naclerio is qualified to serve on our board of directors because of his extensive scientific knowledge, business and operations experience, including as a venture capital investor and a member of the boards of directors of other life sciences businesses.

Ian Ratcliffe has served as a member of our board of directors since February 2024. He is an executive managing partner of the Sands Capital Life Sciences Pulse strategy and an executive managing director of Sands Capital. Before joining Sands Capital, Ian was the chairman and chief executive officer of Enzymatics (now Qiagen), founder and chief executive officer of Stemgent (now Reprocell), and president of Upstate (now MilliporeSigma). Earlier in his career, he founded and led a number of privately held life science businesses spanning cell signaling, drug screening, genomics, sequencing, and cell culture. Ian holds a degree in Chemical Engineering from the University of Surrey and an M.B.A. from the Darden School at the University of Virginia.

Frank Witney has served as a member of our board of directors since January 2026. He is an operating partner at Ampersand Capital Partners. Prior to joining Ampersand, Frank was president and chief executive officer of Affymetrix. Earlier in his career, Frank served as president and chief executive officer of Dionex Corporation, chief commercial officer at Affymetrix, and president and chief executive officer of Panomics. He currently serves on the board of directors of Cerus Corporation, Revvity and Standard BioTools, as well as several privately held companies. Frank earned a B.S. in Microbiology from the University of Illinois as well as a M.S. in Microbiology and a Ph.D. in Molecular and Cellular Biology from Indiana University.